Pfizer announced on Aug. 4 that it will implement an additional $2.5 billion in cuts as part of its ongoing restructuring, with much of the reduction focused on technology and simplification efforts across its commercial, research and development, and manufacturing functions.
The company said these new measures fall under Pfizer’s Realigning Our Cost Base Program and are expected to generate $1 billion in savings primarily between 2027 and 2029. Prior to this announcement, anticipated savings from the program were set at $5.7 billion by the end of 2026; with the extension through 2029, total projected savings now reach $6.7 billion.
In addition to these cuts, Pfizer is working to reduce its cost of goods sold organization-wide by adding another $1.5 billion in expected savings through product portfolio enhancements and operational efficiencies during the same period. The first phase was projected to save $1.5 billion through 2027, bringing total anticipated savings for this initiative to $3 billion after Tuesday’s update.
The restructuring comes as Pfizer seeks stability following revenue declines post-COVID-19 pandemic demand for vaccines like Comirnaty and patent challenges affecting products such as Eliquis. The cost-saving program began in October 2023 after several quarters of falling revenue and has expanded each quarter since then.
To achieve these intended savings, Pfizer expects a one-time cost of $2 billion under the Realigning Our Cost Base Program for digital enablement, implementation, and severance expenses; details about job impacts or specific technological changes were not disclosed by a company spokesperson. Achieving manufacturing-related savings will require an additional one-time cost of $4 billion—about 60% non-cash expenditures including asset write-downs, with the remainder allocated for severance, implementation costs, and exit expenses.
Pfizer also reported pipeline adjustments alongside mixed second-quarter earnings results: multiple pipeline assets were cut—including MET-224o (PF'6796) acquired from Metsera—and a Phase 2 GIPR antagonist was discontinued following data review from Novo Nordisk’s liraglutide study; however, Pfizer said it remains committed to developing oral peptide approaches targeting GLP-1 receptors.
